Recent News

• 06.13.2025 - Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
• 06.13.2025 - Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
• 06.04.2025 - Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
• 06.04.2025 - Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
• 05.19.2025 - Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
• 05.19.2025 - Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
• 05.17.2025 - Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
• 05.17.2025 - Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Recent Filings

• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1
• 05.19.2025 - 8-K Current report